Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Material Agreement (Jan 18, 2024)

Reports
Material Agreements·Financial Events
Filing Date
Filed January 18, 2024
Period End
January 17, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · May ’23May ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed January 18, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. entered into two financing arrangements on January 17, 2024 (the Closing Date) and used the proceeds to refinance its existing loan.

First, under a Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l., the Purchasers agreed to pay the Company $500,000,000a (net of certain transaction expenses) upon the first FDA approval of acoramidis. In return, the Purchasers receive royalty payments equal to 5% of global Net Sales of acoramidis, payable quarterly after the Funding Date, and the Seller Parties granted a security interest in specific acoramidis-related assets. The Purchasers' rights terminate upon the earlier of receipt of royalty payments totaling $950,000,000 (the Cap Amount) or a buy-out payment not exceeding the Cap Amount.

The royalty rate may adjust to a maximum of 10% in 2027 under certain sales-performance conditions. If a change in control occurs before FDA approval, either party may terminate and the Seller Parties must pay $25,000,000b. Second, under a Financing Agreement with Blue Owl Capital Corporation as administrative agent, the Lenders extended a senior secured credit facility of up to $750,000,000, consisting of a $450,000,000 Initial Term Loan (funded on the Closing Date) and up to $300,000,000 in incremental term loans available by mutual consent.

The Term Loans bear interest at the base rate plus 5.75% (with a base rate floor of 2.00%) or three-month Term SOFR plus 6.75% (with a 1.00% floor). Principal payments of $22,500,000c begin June 30, 2027, and the stated maturity is January 17, 2029, subject to springing earlier maturities tied to outstanding convertible senior notes. The Company must maintain at least $70,000,000 of unrestricted cash, and prepayment fees can reach 3.00% of the Term Loans prepaid, plus a make-whole amount.

The Company used the Initial Term Loan proceeds and cash on hand to repay all outstanding amounts under its Loan and Security Agreement dated November 17, 2021, which was terminated and had its guarantees and liens released on the Closing Date. Both agreements' full texts will be filed as exhibits to a later periodic report.

Key Highlights

  1. $500,000,000 Funding Agreement payable upon first FDA approval of acoramidis, in exchange for a 5% royalty on global Net Sales of acoramidis, capped at $950,000,000 in royalty payments.
  2. Royalty rate may adjust to a maximum of 10% in 2027 under certain acoramidis sales-performance conditions.
  3. $750,000,000 senior secured credit facility from Blue Owl-led lenders, including a $450,000,000 Initial Term Loan funded at closing and up to $300,000,000 in incremental loans.
  4. Term Loan interest rates are base rate plus 5.75% or Term SOFR plus 6.75%, with a minimum unrestricted cash balance of $70,000,000 required.
  5. Stated maturity of January 17, 2029, with $22,500,000 principal payments beginning June 30, 2027, and springing earlier maturities tied to convertible notes exceeding $50 million.
  6. Existing Loan Agreement with U.S. Bank National Association was repaid and terminated using Initial Term Loan proceeds and cash on hand.
  7. A change in control before FDA approval of acoramidis allows either party to terminate the Funding Agreement, with a $25,000,000 payment owed by the Seller Parties.

Frequently Asked Questions

  1. How much capital is the Company receiving under the Funding Agreement, and when?

    The Purchasers agreed to pay $500,000,000 (net of certain transaction expenses) upon the first FDA approval of acoramidis, subject to certain conditions.

  2. What does the Company give up in exchange for the Funding Agreement payment?

    The Company grants the Purchasers royalty payments equal to 5% of global Net Sales of acoramidis, payable quarterly after the Funding Date, and grants a security interest in specific acoramidis-related assets. These rights end once royalties total $950,000,000 or upon a buy-out payment.

  3. What is the size and cost of the new senior secured credit facility?

    The facility totals up to $750,000,000, including a $450,000,000 Initial Term Loan funded at closing and up to $300,000,000 in incremental term loans. Interest is base rate plus 5.75% or Term SOFR plus 6.75%, and prepayment fees can reach 3.00% of the amount prepaid plus a make-whole amount.

  4. When do the Term Loans mature and when must principal be repaid?

    The stated maturity date is January 17, 2029, with principal payments of $22,500,000 on the Initial Term Loan beginning June 30, 2027. Two springing earlier maturities apply 91 days before the maturity of the Company's convertible senior notes if more than $50 million of those notes remain outstanding.

  5. What happens to the Company's prior debt and what are the key covenants?

    The Company repaid all outstanding principal, interest and fees under its Loan and Security Agreement dated November 17, 2021, which was terminated with its guarantees and liens released. The new facility requires a minimum unrestricted cash balance of $70,000,000 at all times and includes customary covenants and a change-of-control event of default.